Home › NDC Lookup › 70512-0013-15
LenzaPro Flex Lidocaine/Menthol 40 mg/g; 40 mg/g Patch, 3 pouches — NDC 70512-0013-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

LenzaPro Flex Lidocaine/Menthol 40 mg/g; 40 mg/g Patch, 3 pouches — NDC 70512-013-15 (Billing 70512-0013-15)

by SOLA Pharmaceuticals · 3 POUCH in 1 BOX / 1 g in 1 POUCH

This is a package of 3 pouches of LenzaPro Flex Lidocaine/Menthol 40 mg/g; 40 mg/g Patch from SOLA Pharmaceuticals, marketed since Feb 2021 and currently FDA-listed. It is this product's only package size.

NDC 70512-0013-15
🏷️ FDA NDC (as labeled) 70512-013-15 billing pads the product segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70512-013-15 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
70512 labeler · 013 product · 15 package
Package marketed since
Feb 1, 2021
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
3 EA per package
Barcode (UPC)
0070512013157
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70512-013-15
Product NDC 70512-013
11-digit billing NDC 70512001315
NCPDP billing unit EA — each (per item)
RxCUI 2572014
UNII L7T10EIP3A, 98PI200987
UPC 0070512013157
Application # M017
SPL Set ID ba498f1d-460b-f4e6-e053-2995a90a5755
Established class (EPC) Amide Local Anesthetic; Antiarrhythmic
Physiologic effect Local Anesthesia
Chemical class Amides
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-02-01
Route TOPICAL
Dosage form PATCH
Substance MENTHOL; LIDOCAINE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90859902885950
GPI class LenzaPro Flex Patch
GCN Seq No 081969
GCN 46292
HICL code 036762
Ingredient (HICL) Lidocaine Hcl/Menthol
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5H
Therapeutic class — specific (HIC3) Topical Local Anesthetics
AHFS code 72:00.00.00
AHFS class Local Anesthetics
FDB label name LENZAPRO FLEX 4%-4% PATCH
FDB brand name Lenzapro Flex
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 081969
  • GCN: 46292
  • GPI-14 (Medi-Span): 90859902885950
  • HICL (First Databank): 036762
  • AHFS class code: 72:00.00.00
  • RxCUI (RxNorm): 2572014
Why two NDCs? The FDA registers this code as 70512-013-15 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70512-0013-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antiarrhythmic class.

Pharmacologic class Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC) Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name LENZAPRO FLEX 4%-4% PATCH Ingredient Lidocaine Hcl/Menthol
🧪 What is this product?

LenzaPro Flex is a topical patch containing lidocaine and menthol. It is an over-the-counter monograph drug, meaning it is marketed under FDA guidelines for this product category without individual approval of this specific brand. Lidocaine is a local anesthetic typically used to numb pain in the skin and tissues, while menthol is commonly added for a cooling sensation. This patch form is applied directly to the skin over the area where relief is sought.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70512-0013-15 You're viewing this Main listing 3 POUCH in 1 BOX / 1 g in 1 POUCH 2021-02-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
LenzaPro Flex 40 mg/g; 40 mg/gthis 70512-0013-15 SOLA 3 pouches — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Feb 2021
📍
2026
Currently FDA-listed
5 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

ShapeRectangle
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII J94PBK7X8S
    A synthetic polymer derived from acrylic acid monomers. In medicines, it's used as a binder to hold tablet ingredients together and sometimes as a coating agent to control where and how the drug releases in the body.

1 inactive ingredient listed in the exact product block matched to this NDC.

The official label also statesOther Ingredients: Acrylic Adhesive

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSOLA Pharmaceuticals
FDA applicationM017 (OTC MONOGRAPH DRUG)
Labeler code70512
First marketedFeb 2021
Product typeHuman Otc Drug
Portfolio12 products on file

More NDCs from SOLA Pharmaceuticals labeler code 70512

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Other Information 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 7 words ▾

Uses: For the temporary relief of pain

⏱️ Dosage and Administration 57 words ▾

Directions: Adults and children over 12 years: Clean and dry the affected area. Open pouch and remove one patch. Remove the protective film from the patch and apply patch to the affected area. Reseal pouch containing unused patches after each use. Use 1 patch for up to 12 hours. Children 12 years or younger: Ask a doctor

⚠️ Warnings 4 words ▾

Warnings: For external use

🧪 Active Ingredient 7 words ▾

Active ingredients: Lidocaine HCL 4% Menthol 4%

🧪 Inactive Ingredients 4 words ▾

Other Ingredients: Acrylic Adhesive

🎯 Purpose 3 words ▾

Purpose: Topical Anesthetic

📄 Do Not Use 32 words ▾

Do not use: More than 1 patch on your body at a time or on cut, iritated or swollen skin. On puncture wounds For more than 1 week without consulting a doctor

📄 When Using This Product 118 words ▾

When using this product: Use only as directed. Read and follow all directions and warnings on this label. Rare cases of serious burns have been reported with products of this type.

Do not apply to wounds or damaged, broken or irritated skin. Do not allow contact with the eyes and mucous membranes. Do not bandage tightly or apply local heat (such as heating pads) to the area of use.

Do not use at the same time as other topical analgesics. Dispose of used patch in manner that always keeps product away from children and pets. Used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch.

📄 Stop Use and Ask a Doctor If 48 words ▾

Stop use and ask a doctor if: Condition worsens Redness is present Irritation developes Symptoms persist for more than 7 days or clear up and occur again within a few days. You experience signs of skin injury, such as pain, swelling, or blistering where the product was applied.

🤰 If Pregnant or Breast-Feeding 11 words ▾

If pregnant or breast-feeding, ask a health care professional before use.

📄 Keep Out of Reach of Children 21 words ▾

Keep out of reach of children and pets. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 13 words ▾

Other Information: Avoid storing product in direct sunlight Protect product from excessive mositure

📄 Package Label / Principal Display Panel 27 words ▾

Questions or comments? 866-747-7365 Manufactured For: SOLA Pharmaceuticals LLC Baton Rouge, LA 70810 NDC: 70512-013-15 QTY: 15 Articulated patches (5 per Resealable Pouch) x 3 Lenzapro Flex

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Lidocaine/Menthol — the ingredient across all brands.

Top reported reactions

Pain3,217
Fatigue3,056
Nausea3,046
Headache2,815
Dyspnoea2,181
Pneumonia2,007
Diarrhoea1,981

Age at onset

Neonate144
Infant62
Child366
Adolescent259
Adult4,987
Elderly3,158

Reporter sex

49,320 reports
Male · 37%
Female · 63%
Unknown · 0%

Serious outcomes

Hospitalization17,575
Death4,981
Life-threatening4,202
Disabling1,205
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5,427 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by SOLA Pharmaceuticals. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
SOLA Pharmaceuticals is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 70512-0012-30 · SOLA 70512-0014-30 · SOLA →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.